A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations. Types:
Subprotocol A: BRAF Fusions in Primary CNS and Other Solid Tumors,
Subprotocol B: BRAF V600 Mutated Recurrent Primary CNS Tumors, Subprotocol C: Rare BRAF V600 Mutated Solid Tumors (non-CNS),
Subprotocol D: Selected BRAF Altered Solid Tumors
